The extreme dilution (379% share increase) and warrant overhang (79% of new share count) will pressure the stock. Monitor for early warrant exercises via zero-cash — any such exercise would add further supply without cash benefit. The 180-day lock-up prevents immediate insider selling but does not prevent warrant holder sales of underlying shares after exercise.
Price Chart
Executive Summary
Basel Medical Group Ltd closed a registered direct offering of 6,000,000 units at $1.33/unit, raising $7.98M gross ($7.28M net). The offering massively dilutes existing shareholders — shares outstanding increased from 1,582,111 to 7,582,111 (a 379% increase), plus 6,000,000 Common Warrants exercisable at $1.463 with a zero-cash exercise option, creating additional overhang. The company expects no additional cash from warrant exercises. A 180-day lock-up applies to insiders and the company.
Key Facts
- Closed registered direct offering of 6,000,000 units at $1.33/unit on October 9, 2026
- Gross proceeds of $7.98 million; estimated net proceeds of approximately $7.28 million
- Shares outstanding increased from 1,582,111 to 7,582,111 — a 379% increase
- 6,000,000 Common Warrants issued, exercisable at $1.463 (110% of offering price) for five years
- Warrants include a zero-cash exercise option; company expects no additional cash from warrant exercises
- If all warrants exercised on zero-cash basis, 6,000,000 additional shares would be issued with no cash proceeds
- 180-day lock-up on insiders and company from further equity issuance without placement agent consent
- Proceeds to be used for working capital, M&A, and general corporate purposes
Financial Impact
Massive dilution: share count increased ~379% from 1.58M to 7.58M shares; potential future dilution of up to 6M additional shares from warrants. Net proceeds of $7.28M represent ~$0.96 per pre-offering share but only ~$0.96 per post-offering share.
Risk Factors
- Massive immediate dilution of ~379% from pre-offering share count
- Warrant overhang of 6M shares (79% of current outstanding) exercisable at $1.463 with zero-cash option — likely to be exercised if stock trades above $1.463, adding further supply
- No additional cash expected from warrant exercises, so dilution provides no capital benefit
- Use of proceeds for M&A introduces execution risk
- Small market cap and low liquidity amplify price impact of any selling
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001493152-26-046677 |
| Exhibit: ex99-1.htm | 0001493152-26-046677 |
| Document: form6-k.htm | 0001493152-26-046677 |
| Document: 0001493152-26-046677-index-headers.html | 0001493152-26-046677 |
| Document: 0001493152-26-046677-index.html | 0001493152-26-046677 |
| Document: 0001493152-26-046677.txt | 0001493152-26-046677 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 6-K | $3.85 $3.85 | · 0.00% | ▼ −1.08% | $4.44 (−15.32%) |
Oct 9, 2026 17d ago | 6-K | $3.75 $3.71 | ▲ +1.07% | ▲ +1.01% | $4.44 (−18.40%) |
Oct 8, 2026 18d ago | 424B4 | $3.75 $3.71 | ▲ +1.07% | ▲ +1.01% | $4.44 (−18.40%) |
Sep 30, 2026 26d ago | EFFECT | $3.12 $3.02 | ▼ −3.21% | ▼ −3.38% | $4.44 (+42.31%) |
Sep 2, 2026 7w ago | 6-K | $4.94 $4.78 | ▼ −3.24% | ▼ −4.29% | $4.44 (−10.12%) |
Aug 10, 2026 11w ago | 6-K | $4.90 $4.99 | ▼ −1.84% | ▼ −2.16% | $4.44 (+9.39%) |
Jul 10, 2026 15w ago | 6-K | $6.61 $6.14 | ▼ −7.04% | ▼ −6.27% | $4.44 (−32.78%) |
Jun 10, 2026 19w ago | 6-K | $0.5869 $0.5783 | ▼ −1.47% | ▼ −3.17% | $4.44 (+656.52%) |
Jun 5, 2026 20w ago | 6-K | $0.5445 $0.5946 | ▲ +9.20% | ▲ +8.97% | $4.44 (+715.43%) |
Mar 30, 2026 30w ago | 6-K | $6.60 $7.08 | ▲ +7.27% | ▲ +4.37% | $4.44 (−32.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers